Receptos

96 articles about Receptos

• 

  Readers' Picks: Top 10 Stories of 2018

  12/28/2018

  As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
• 

  Celgene Brings in Merck KGaA Vet as Part of an Effort to Fix Clinical Development Woes

  10/23/2018

  Following several clinical disappointments and declining stock prices over the past year, Celgene tapped Alise Reicin as its new head of the company’s global clinical development unit, with a focus on mid- to late-stage therapeutics.  
• 

  Promising Data for Celgene's Revlimid

  7/24/2018

  Celgene announced data from its Phase III AUGMENT clinical trial that compared Revlimid (lenalidomide) and rituximab to placebo in relapsed/refractory follicular and marginal zone lymphoma.
• 

  Celgene’s Phase III Trial of Tecentriq and Abraxane Hits Co-Primary Endpoints

  7/10/2018

  Celgene Corporation announced that its Phase III IMpassion130 trial, sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS).
• 

  Top 10 Stories of the First Half of 2018

  7/6/2018

  It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
• 

  Celgene Admits It Screwed Up on Multiple Sclerosis Drug Application … Sort Of

  6/13/2018

  This year the FDA issued a Refusal to File letter regarding its New Drug Application (NDA) for its multiple sclerosis drug ozanimod. The finger is pointed at its California subsidiary, Receptos for the failure.
• 

  Two Former Receptos Execs Launch New San Diego Biotech Startup With $100M

  1/5/2018

  It is not clear what the new company's focus is just yet.

• Vital Therapies Appoints Former Receptos President And CEO Faheem Hasnain As Chairman Of The Board Of Directors

  9/6/2017

• Vital Therapies Announces Appointment Of Former Receptos President And CEO Faheem Hasnain To Its Board Of Directors

  8/15/2016

• Celgene Completes Acquisition Of Receptos, Advancing Leadership In Immune-Inflammatory Diseases

  8/28/2015

• Celgene Announces Expiration Of Cash Tender Offer For Shares Of Receptos

  8/25/2015

• Celgene Receives Antitrust Clearance For Receptos Acquisition

  8/11/2015

• Celgene Commences Tender Offer For Receptos

  7/28/2015

• Celgene Swallows Up SoCal's Receptos in $7.2 Billion Deal

  7/17/2015

• Bidding War Could Push Receptos Price From $211 to $348 a Share

  6/18/2015

• Receptos Allegedly Rebuffs AstraZeneca PLC Bid But Rivals Gilead, Teva are Circling

  6/11/2015

• Receptos To Present At Jefferies and Co. 2015 Global Healthcare Conference

  5/28/2015

• Receptos Announces Oral Plenary Presentation Of TOUCHSTONE Phase II Induction Data At Digestive Disease Week 2015

  5/15/2015

• Receptos To Present At UBS Global Healthcare Conference

  5/14/2015

• Receptos To Present At Bank of America Merrill Lynch 2015 Healthcare Conference

  5/7/2015